GERMANTOWN, Maryland and HILDEN, Germany, January 9, 2017 /PRNewswire/ --
QIAGEN N.V. (NASDAQ: QGEN; Frankfurt Prime Standard: QIA) today announced the submission of QuantiFERON(R)-TB Gold Plus (QFT(R)-Plus), the fourth generation of the modern blood test for detecting tuberculosis (TB) infection, for pre-market approval (PMA) by the U.S. Food and Drug Administration (FDA).
The U.S. submission follows the launch during 2016 and positive uptake of QuantiFERON-TB Gold Plus in more than 60 countries across Europe, the Middle East, Africa, Asia and Latin America, where more than 600,000 of the new tests have already been used.
QFT-Plus builds on the foundation of QuantiFERON-TB Gold(R) (QFT(R)), the third-generation version of the world's leading interferon gamma release assay (IGRA), which has been established as a cost-effective and efficient tool for TB infection testing with more than 30 million tests conducted worldwide since its initial launch. The fourth-generation QFT-Plus test adds proprietary CD8 antigens and workflow improvements that allow for even more efficient implementation, especially in large-scale TB screening programs. These include a single-tube blood collection option, as well as the current use of the unique "assay in collection tube" design that allows for immediate stimulation of the blood sample.
Click here [https://www.qiagen.com/about-us/press-releases/pressreleaseview?ID=%7b128CDBC1-6FFD-49DE-BEFC-5327DC7BFD67%7d&lang=en ] for full press release
https://www.qiagen.com/about-us/press-releases/pressreleaseview?ID={128CDBC1-6FFD-49DE-BEFC-5327DC7BFD67}&lang=en
QIAGEN contacts: Investor Relations John Gilardi +49-2103-29-11711 Dr. Sarah Fakih +49-2013-29-11457 e-mail: ir@QIAGEN.com Public Relations Dr. Thomas Theuringer +49-2103-29-11826 e-mail: pr@QIAGEN.com
SOURCE QIAGEN N.V.